{"id":"W2024930123","doi":"10.1016/s0140-6736(14)61399-4","title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":751,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Clinical Research Institute; Université de Montréal","funders":"Ipsen; Novo Nordisk; Otsuka America; Novartis; AbbVie; Genzyme; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Bayer HealthCare; Meso Scale Diagnostics; Sanofi; Merck; Abbott Laboratories","keywords":"Evolocumab; Ezetimibe; Medicine; Placebo; PCSK9; Familial hypercholesterolemia; Cholesterol; Statin; Alirocumab; Internal medicine; Clinical trial; Dosing; Ldl cholesterol; Gastroenterology; Endocrinology; Lipoprotein; LDL receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0287132061087211,"score_gpt":0.2783745620263545,"score_spread":0.2496613559176334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}